States Target Mylan (MYL) Exec Malik in Generic Drug-Collusion Probe - Bloomberg

(Updated - October 31, 2017 11:04 AM EDT)

Dozens of states are targeting Mylan (NASDAQ: MYL) president and executive director Rajiv Malik in a generic drug-collusion probe, Bloomberg reported.

State AGs are seeking to sue Rajiv Malik as part of an expanded complaint against pharmaceutical companies, according to a statement by Connecticut Attorney General George Jepsen.

Malik would be the first senior executive from a major drugmaker sued in the case.

"These conspiracies were part of a much broader, overarching industry code of conduct that enabled the defendant manufacturers to divvy up the market for specific generic drugs in accordance with an established, agreed-upon understanding for assigning each competitor their share of the market," Jepsen said in the statement.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• Shake Shack initiated at Strong Sell at Off Wall Street
• J&J myeloma drug combo cuts disease progression risk by 89% in trial